Ascorbate in Myelodysplastic Syndrome

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-05-01

Summary

This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.

• Phase: PHASE2

Details

• Lead Sponsor: Prajwal Dhakal
• Treatments: Ascorbic Acid; Azacitidine